Key facts
- PepLib’s last known valuation is $86.1M (Jul 2019).
- It has raised $62.1M; the latest was Later Stage VC ($13.9M) in Jul 2025.
- Notable investors include Cowin Capital, Fortune Capital, CDH Investments, Legend Star, CAS Investment Management — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for PepLib
- ·The full record, as it builds
Funding rounds
No funding rounds for PepLib are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PepLib
Developer of peptide-leading drugs intended to serve the medical sector in China. The company is platform-based, specialized in the discovery of peptide-leading drugs, focusing on development, production, sale of large-capacity peptide libraries and development of technical services for the screening of new peptides.
- Sector
- Healthcare
- HQ
- Zhuzhou, China
- Founded
- 2017
- Employees
- 200
- Website
- peplib.cn/
- Ownership
- Privately Held (backing)
PepLib doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PepLib shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PepLib in its N-PORT filings yet. We sweep new filings monthly.